DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for subacute thyroiditis — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSubacute thyroiditis maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for subacute thyroiditis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
prostaglandin-endoperoxide synthase 2 (PTGS2) — PTGS2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet saldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5F1A · 2.38 Å · ligand 2-HYDROXYBENZOIC ACID (SAL). Experimental structure, not a prediction.
What the evidence adds up to
A 2021 case report describes a man in his forties diagnosed with subacute thyroiditis after a mild COVID-19 infection. The authors note that subacute thyroiditis is thought to be initiated by a viral infection or postviral inflammatory process, often in patients with a history of an upper respiratory infection two to eight weeks before onset. They state the condition is believed to be triggered by an antigen created by the virus. Another 2021 case report describes a 43-year-old woman who developed subacute thyroiditis six weeks following COVID-19. Neither report provides any data on treatment, response rates, or survival.
A 2019 paper titled "Multidisciplinary approach to the diagnosis and treatment of subacute thyroiditis" does not actually study subacute thyroiditis. Its abstract describes a study of 26 patients with acute and chronic wounds of various genesis, examining clinical and morphological criteria of wound healing. It contains no information about subacute thyroiditis, its diagnosis, or its treatment.
No drug treatment for subacute thyroiditis is mentioned in any of these abstracts. The evidence is limited to two single-patient case reports linking the condition to prior COVID-19 infection. What is missing is any controlled trial, any comparison of treatment approaches, any data on patient stratification by severity or viral history, and any funding for prospective studies of this post-viral complication.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1960 · 19 citations
SUBACUTE THYROIDITIS
AbstractSubacute thyroiditis often escapes recognition, although the diagnosis is easy if the possibility is kept in mind. Of the 13 cases summarized here, only 6 were diagnosed by the first physician who saw the patient, and in 3 cases it was the fourth physician who made the diagnosis. The most important diagnostic clue was palpation of the thyroid, which would often have sufficed to distinguish between thyroiditis and pharyngitis. The disease is generally self-limited, and patients with mild cases need only aspirin. Steroid therapy is purely symptomatic. In most patients it brings about relief from pain, swelling, and fever within the first day or two. One patient had relapses on three occasions when it was discontinued or the dose lowered prematurely.
Tidsskrift for Den norske legeforening · 2021 · 16 citations · open access
Subacute thyroiditis after COVID-19
AbstractBACKGROUND: Since the beginning of the pandemic we have learned much about acute organ complications due to COVID-19, but we are still only beginning to understand the post-infection complications. CASE PRESENTATION: A man in his forties was diagnosed with subacute thyroiditis after a mild COVID-19 infection. This is an important differential diagnosis to consider if after a period of improvement, an infected patient develops fever, pain around the region of the thyroid (throat/neck) and/or symptoms of hyperthyroidism. INTERPRETATION: Subacute thyroiditis is thought to be initiated by a viral infection or postviral inflammatory process, often in patients with a history of an upper respiratory infection typically two to eight weeks prior to the onset of thyroiditis. The condition is believed to be triggered by an antigen created by the virus. Subacute thyroiditis must be on the list of possible differential diagnoses in patients with COVID-19 whose condition deteriorates after a period of improvement.
Journal of Contemporary Medical Sciences · 2021 · 1 citations · open access
Post COVID-19 Subacute thyroiditis: A case report
AbstractSubacute thyroiditis is a non-suppurative inflammation of the thyroid gland, which usually develops after viral infection to the upper respiratory tract, accompanied by pain in the neck radiated to the jaw and fever. This is a case report study for a 43-year-old woman, who developed subacute thyroiditis 6 weeks following coronavirus disease (COVID-19).
Journal of the Grodno State Medical University · 2019 · 0 citations · open access
MULTIDISCIPLINARY APPROACH TO THE DIAGNOSIS AND TREATMENT OF SUBACUTE THYROIDITIS
AbstractBackground. The chronicity of the wound is a factor leading to a greater number of postoperative complications when performing plastic closure of wound defects and requires the use of special methods of preoperative preparation. In clinical practice, it is important to use precise clinical and morphological criteria to assess the activity of the inflammatory response and the degree of impairment of the proliferative phase of the reparative process. Aim. To determine the features of clinical parameters of the local status of wound defects and their correspondence to morphological criteria in patients with acute and chronic wounds of various genesis. Material and Methods. Clinical signs of acute and chronic wounds in 26 patients with different types and duration of integumentary tissue defects were described. In a hospital setting, a morphological study of the biopsy specimens from wounds and surrounding tissues was performed to identify histological signs of chronic wound healing. The correspondence between clinical and morphological signs of acute and chronic wounds was analyzed. Results. The initial study of the local status of wound defects did not reveal significant differences in the clinical signs of acute and chronic wounds. Histological examination of the wound biopsy specimens revealed morphological signs of chronic wound healing. Conclusion. Evaluation of clinical signs of the local wound status is necessary to identify the dynamics of wound parameters during treatment. Histological examination of wound biopsy specimens makes it possible to more reliably identify signs of chronicity of the wound.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
